CD8A and nonpapillary renal cell carcinoma: Even though CD8+ T cells have long been regarded to be a critical type of cell in the development and progression of malignancies, recent new immunotherapies targeting immunological checkpoints as the standard of care have altered the treatment paradigm of ccRCC [10, 11], a sizable CD8+ T cell fraction of patients with ccRCC do not respond to these treatments and those who do at first progress.